Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FUG
|
|||
| Drug Name |
Treprostinil palmitil
|
|||
| Synonyms |
Treprostinil palmitil; treprostinil hexadecyl ester; Hexadecyl treprostinil; INS1009; 1706528-83-7; Treprostinil palmitil [INN]; Treprostinil palmitil [USAN]; 8GJK87S89F; UNII-8GJK87S89F; Treprostinil palmitil [USAN:INN]; INS-1009; WHO 11087; hexadecyl 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetate; CHEMBL4650232; SCHEMBL22596768; GLXC-26976; AKOS040756993; MS-30736; HY-109163; CS-0116342; Q27270416; ACETIC ACID, 2-(((1R,2R,3AS,9AS)-2,3,3A,4,9,9A-HEXAHYDRO-2-HYDROXY-1-((3S)- 3-HYDROXYOCTYL)-1H-BENZ(F)INDEN-5-YL)OXY)-, HEXADECYL ESTER; HEXADECYL 2-(((1R,2R,3AS,9AS)-2-HYDROXY-1-((S)-3-HYDROXYOCTYL)-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYCLOPENTA(B)NAPHTHALEN-5-YL)OXY)ACETATE
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 2/3 | [1] | |
| Company |
Insmed Bridgewater, NJ
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C39H66O5
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCCCOC(=O)COC1=CC=CC2=C1CC3CC(C(C3C2)CCC(CCCCC)O)O
|
|||
| InChI |
InChI=1S/C39H66O5/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-19-26-43-39(42)30-44-38-23-20-21-31-27-35-32(28-36(31)38)29-37(41)34(35)25-24-33(40)22-18-6-4-2/h20-21,23,32-35,37,40-41H,3-19,22,24-30H2,1-2H3/t32-,33-,34+,35-,37+/m0/s1
|
|||
| InChIKey |
XOKCXRVJBBLBSX-HDMCCQRMSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05649748) An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.